Email updates

Keep up to date with the latest news and content from JTM and BioMed Central.

This article is part of the supplement: 6th European Workshop on Immune-Mediated Inflammatory Diseases

Open Access Poster presentation

A subset of dendritic cells as a major and constitutive source of IL-22BP

Jérôme Martin12, Gaelle Bériou1, Michèle Heslan1, Céline Bossard3, Anne-Chantal Knol4, Brigitte Dréno4, Simon Milling5, Miriam Merad6 and Régis Josien12*

  • * Corresponding author: Régis Josien

Author Affiliations

1 INSERM U643, ITUN, Nantes, France

2 Laboratoire d’Immunologie, Nantes, France

3 Service d’Anatomo-Pathologie, Nantes, France

4 INSERM U892, Laboratoire d’Immuno-Dermatologie, CHU Nantes, Nantes, France

5 University of Glasgow, Glasgow, UK

6 Mount Sinai School of Medicine, New York, USA

For all author emails, please log on.

Journal of Translational Medicine 2011, 9(Suppl 2):P2  doi:10.1186/1479-5876-9-S2-P2


The electronic version of this article is the complete one and can be found online at: http://www.translational-medicine.com/content/9/S2/P2


Published:23 November 2011

© 2011 Martin et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

IL-22 is a cytokine produced by T cells and innate lymphocytes. Its receptor is exclusively expressed by non hematopoietic cells mostly epithelial cells and hepatocytes. IL-22 has pathogenic or protective effects depending on the model. A role for IL-22 is suggested in IMID such as psoriasis, rheumatoid arthritis and Crohn disease. IL-22BP is a soluble inhibitory receptor specific for IL-22 whose cellular source and physiological role are mainly unknown.

Aims

To identify the cellular source of IL-22BP in vivo and its regulation of expression.

Methods

Rat dendritic cells (DCs) were prepared from spleen. Human DCs were derived from monocytes (MDDC) in the presence of GM-CSF+IL-4. IL-22BP mRNA expression was assessed by q-PCR. Immunostaining experiments were performed with polyclonal and/or monoclonal Ab to IL-22BP. IL-22BP in serum was identified by WB.

Results

IL-22BP mRNA was expressed at high levels in rat secondary lymphoid organs and intestine. In spleen, IL-22BP mRNA was restricted to a CD4+SIRPA+ subset of DCs. This expression was constitutive. Similar results were obtained in lymph nodes. IL-22BP expression in DCs was confirmed at the protein level. An even stronger expression was found in a subset of lymph DCs migrating from gut. In mouse, IL-22BP expression appeared restricted to the CD103+ subsets of intestine DCs. In human, immunostaining experiments identified stellate IL-22BP+ cells in colon lamina propria and dermis. In vitro, IL-22BP expression was induced during MDDC differentiation and retinoic acid receptor alpha agonist dramatically enhanced this expression. IL-22BP expression was rapidly down-regulated following maturation both in rat and human DC. Finally, WB analysis revealed high levels of serum IL-22BP in healthy volunteers.

Conclusion

These results indicate that tissue and lymphoid DCs are a main source of IL-22BP suggesting a role for these DCs in regulating IL-22 at epithelial barriers.